Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERBB2 | P04626 | 4/20 | 0.44 |
| ▸ | CRHR1 | P34998 | 3/20 | 0.41 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.39 |
| ▸ | HSP90AB1 | P08238 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7036139 | 0.89 | ERBB2 (0.44) | ERBB2CRHR1HSP90AA1HSP90AB1 | |
| SCHEMBL7031052 | 0.89 | ERBB2 (0.56) | ERBB2CRHR1HSP90AA1HSP90AB1 | |
| SCHEMBL7033254 | 0.88 | ERBB2 (0.44) | ERBB2CRHR1HSP90AA1HSP90AB1 | |
| SCHEMBL7029124 | 0.88 | ERBB2 (0.55) | ERBB2CRHR1HSP90AA1HSP90AB1 | |
| SCHEMBL7033056 | 0.88 | ERBB2 (0.55) | ERBB2CRHR1HSP90AA1HSP90AB1 | |
| SCHEMBL6077779 | 0.84 | CRHR1 (0.44) | ERBB2CRHR1 | |
| SCHEMBL7032141 | 0.84 | HSP90B1 (0.45) | ERBB2CRHR1HSP90AA1HSP90AB1 | |
| SCHEMBL7032248 | 0.83 | HSP90B1 (0.44) | ERBB2CRHR1HSP90AA1HSP90AB1 | |
| SCHEMBL7036738 | 0.83 | ERBB2 (0.43) | ERBB2CRHR1HSP90AA1HSP90AB1 | |
| SCHEMBL7028964 | 0.83 | HSP90B1 (0.44) | ERBB2CRHR1HSP90AA1HSP90AB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7045529-B2 | Imidazopyrimidinyl and imidazopyri dinyl derivatives | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-05-16 | — | — | US | disclosed |
| US-20040229887-A1 | Novel imidazopyrimidinyl and imidazopyri dinyl derivatives | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2004-11-18 | — | — | US | disclosed |
| EP-1244666-A1 | IMIDAZOPYRIMIDINYL AND IMIDAZOPYRIDINYL DERIVATIVES | Bristol-Myers Squibb Pharma Company (US) | 2002-10-02 | — | — | EP | disclosed |
| WO-2001044248-A1 | IMIDAZOPYRIMIDINYL AND IMIDAZOPYRIDINYL DERIVATIVES | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2001-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040229887-A1 | Novel imidazopyrimidinyl and imidazopyri dinyl derivatives | CRH, GPR119, CRHR1 | ERBB2 3467/4885CRHR1 3/4885HSP90AA1 445/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.